39794-77-9

Usage

Uses

An intermediate of Cefmetazole (C242850).

InChI:InChI=1/C9H10O5S/c1-7-2-4-8(5-3-7)15(12,13)14-6-9(10)11/h2-5H,6H2,1H3,(H,10,11)

Upstream product

• 50-00-0 formaldehyd 
• 151-50-8 potassium cyanide 
• 98-59-9 p-toluenesulfonyl chloride 
• 79-14-1 glycolic Acid 
• 64-69-7 Iodoacetic acid 
• 16836-95-6 silver(I) 4-methylbenzenesulfonate 
• 39794-75-7 ethyl α-p-toluenesulfonyloxyacetate 

Downstream Products

• 158818-29-2 N-phenyl-O-tosylglycolamide 
• 501919-59-1 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]benzoic acid 
• 959119-78-9 4-(2-(tosyloxy)acetamido)benzoic acid 
• 1334484-14-8 2-((2,5-dimethoxybenzyl)(2-phenoxyphenyl)amino)-2-oxoethyl-4-methylbenzenesulfonate 
• 76273-08-0 7-tosyloxyacetamido-3-deacetoxycephalosporanic acid 
• 76273-02-4 (Toluene-4-sulfonyloxy)-acetic acid quinolin-8-yl ester 

Relevant academic research and scientific papers

Synthesis of thioether andrographolide derivatives and their inhibitory effect against cancer cells

A series of novel thioether andrographolide derivatives were synthesized by incorporating various aromatic (or heteroaromatic) substituents into C-12 or 14-OH. A total of 38 andrographolide derivatives were prepared and evaluated for their in vitro inhibi

Synthesis of [11C]PBR06 and [18F]PBR06 as agents for positron emission tomographic (PET) imaging of the translocator protein (TSPO)

The translocator protein 18 kDa (TSPO) is an attractive target for molecular imaging of neuroinflammation and tumor progression. [ 18F]PBR06, a fluorine-18 labeled form of PBR06, is a promising PET TSPO radioligand originally developed at NIMH.

Synthesis and radiofluorination of iodophenyl esters as tool for the traceless staudinger ligation

A new synthetic pathway for the preparation of ω-functionalized 2-iodophenyl esters as starting materials for the synthesis of substituted phosphanes is described. A radiolabeling of these esters with fluorine-18 has led to building blocks which were reacted with HPPh2 in a Pd-catalyzed P-C cross coupling to establish new phosphanes. These compounds can be applied as mild and bioorthogonal radiolabeling agents by means of the traceless Staudinger ligation. A route to access this class of compounds has been established.

SMALL MOLECULE INHIBITORS OF STAT3 WITH ANTI-TUMOR ACTIVITY

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growthinvitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents.